Home » FDA Begins Safety Review of Bleeding With BI’s Pradaxa
FDA Begins Safety Review of Bleeding With BI’s Pradaxa
The FDA is reviewing postmarket reports of serious bleeding events in patients taking Boehringer Ingelheim’s blood-thinner Pradaxa just as the drug is facing increased competition with approval of Johnson & Johnson and Bayer’s Xarelto in atrial fibrillation (AF) patients.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May